石药集团(01093.HK)与康诺亚生物订立产品授权及商业化协议
格隆汇 3 月 10日丨石药集团(01093.HK)公告,公司全资附属公司上海津曼特生物科技有限公司已与康诺亚生物医药科技(成都)有限公司订立协议,内容有关产品CM310(一种抗IL-4Rα的重组人源化单抗)在中重度哮喘和慢性阻塞性肺病(COPD)等呼吸系统疾病独家授权开发及商业化。
根据该协议,津曼特生物将获得康诺亚生物授出该产品独家权利,以于中华人民共和国(不包括香港特别行政区、澳门特别行政区及台湾地区)进行该产品该于等适应症开发与商业化,并成为上市许可持有人(MAH)。
作为独家授权代价,津曼特生物同意向康诺亚生物支付人民币7000万元首付款及根据该产品于该地区的开发进度支付人民币1亿元开发里程碑付款。津曼特生物亦同意根据该产品于该地区达成销售额向康诺亚生物支付销售里程碑付款和销售提成。
CM310是康诺亚生物研发的具有自主知识产权的靶向人白细胞介素4受体α亚基(IL-4Rα)的重组人源化单克隆抗体注射液。该产品通过与其特异性结合,从而抑制炎症反应,拟用于治疗中重度哮喘,COPD和特应性皮炎等适应症。该产品在中国按治疗用生物制品1类新药申报,中重度哮喘的适应症于2019年7月获临床试验默示许可。CM310目前已经开展临床II期研究工作。
康诺亚生物成立于2016年,是一家专注于创新抗体药物和其它治疗性蛋白药物的创新生物药公司,由具有丰富科技成果转化及国内外产业化经验的专家创办。现有员工200余人。公司已获得包括联想星、高瓴资、汉康资、礼来亚洲基金、三正健康、博裕资等在内的多家国际知名机构投资,在成都、上海及北京设有研究开发和临床药物生产基地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.